BridgeBio Pharma vs ICON
BridgeBio Pharma (BBIO), health care, and ICON (ICLR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BridgeBio Pharma is worth $15B on the stock market and ICON $14.6B: BridgeBio Pharma is valued at 2% more. BridgeBio Pharma's operating margin in its latest fiscal year was -104% and ICON's 5.37%. Over the past year BridgeBio Pharma's share price has moved +17.9% and ICON's +18.9%.
Key facts
- BridgeBio Pharma market value
- $15B
- ICON market value
- $14.6B
- ICON P/E
- 78.0
- BridgeBio Pharma revenue
- $502.1MFY to 2025-12-31
- ICON revenue
- $8.3BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | BridgeBio Pharma | ICON |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $15Bhigher | $14.6Blower |
| Revenue | $502.1Mlower | $8.3Bhigher |
| Earnings | -$732.9Mlower | $229.3Mhigher |
| Employees | 1,081lower | 40,250higher |
| Total assets | $936Mlower | $16.3Bhigher |
| Valuation | ||
| P/E | — | 78.0 |
| P/S | 29.8higher | 1.8lower |
| P/B | — | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | -104%lower | 5.37%higher |
| Balance sheet | ||
| Net assets | -$2.1Blower | $9.2Bhigher |
| Total liabilities | $3Blower | $7.1Bhigher |
| Total debt | $2Blower | $2.9Bhigher |
| Cash on hand | $570.1Mlower | $647.3Mhigher |
| Price change | ||
| Today | -0.72%lower | +1.89%higher |
| 1 year | +17.9%lower | +18.9%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- David Shaw (founder)0.2% / 0.1%
BridgeBio Pharma only (7)
ICON only (12)
- Glenn Greenberg11.2%
- Edgar Wachenheim6.6%
- Sequoia Fund team5.6%
- Anthony Bozza4.6%
- Ron Muhlenkamp (founder)2.8%
- Andrew Wellington2.1%
- Charles Brandes (founder)1.3%
- Steven Romick1.2%
- Bill Nygren1.0%
- Louis Bacon0.4%
- Diamond Hill team0.2%
- Ron Baron0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": BridgeBio Pharma / ICON). Who owns BBIO · Who owns ICLR
More on BridgeBio Pharma
Further comparisons
BridgeBio Pharma against its closest peers
ICON against its closest peers
Learn
Questions and answers
Which is bigger, BridgeBio Pharma or ICON?
By market value, BridgeBio Pharma is the larger: $15B against $14.6B for ICON. By revenue in its latest fiscal year, ICON is the larger: $8.3B against $502.1M for BridgeBio Pharma.
Which has the higher operating margin?
ICON: 5.37%, against -104% for BridgeBio Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
ICON: $2.9B, against $2B for BridgeBio Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both BridgeBio Pharma and ICON?
In their latest 13F filings, David Shaw (founder) holds both.
Cite this page
Funkfolio, “BridgeBio Pharma vs ICON”, data as of 17 November 2026. https://funkfolio.com/compare/bbio-vs-iclr
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.